NEW YORK (GenomeWeb News) – A GlaxoSmithKline study suggests variants in the gene coding for the beta-2 adrenergic receptor do not affect an individual’s response to its asthma drugs Advair Diskus (fluticasone propionate and salmeterol inhalation powder) or Serevent Diskus (salmeterol xinofoate inhalation powder), the company announced yesterday at the American Academy of Allergy, Asthma and Immunology annual meeting in Philadelphia.
The data, presented by Eugene Bleecker, the co-director of Wake Forest University School of Medicine’s Center for Human Genomics, was based on a trial of 544 patients taking Advair or Serevent for 16 weeks. Previous studies indicated that genetic differences in the beta-2 adrenergic receptor affect patient response to beta-agonists such as albuterol.
In contrast, the results of this study suggest that individuals with three different forms of the beta-2 adrenergic receptor all respond similarly to Advair and Serevent based on outcomes such as morning expiratory flow rate, improvement on treatment, forced expiratory volume, and symptom-free days. Another study examining 11 beta-2 adrenergic receptor polymorphisms found no single variation that influenced Advair or Serevent response.
Other data presented at the meeting by Harold Nelson, a researcher at Denver’s National Jewish Medical and Research Center, suggests that variations in the beta-2 adrenergic receptor gene also do not influence the incidence of exacerbated asthma symptoms or related hospital visits.